Back to Search Results

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.

Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Division of Hematology, Chang Gung Memorial Hospital, Chiayi, Taiwan. Department of Hematology, Somogy County Mór Kaposi General Hospital, Kaposvár, 7400, Hungary. Hematology Institute & Blood Bank, Meir Medical Center, Kfar Saba & Sackler School of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel. Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, 08035, Spain. Singapore General Hospital, 169608, Singapore. Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, M5G 2C1, Canada. Guy's & St. Thomas' NHS Foundation Trust, London, SE1 9RS, UK. Centre d'Investigations Cliniques (INSERM CIC 1427), AP-HP, Hopital Saint-Louis, Université de Paris, Paris, 75010, France. Policlinica de Diagnostic Rapid Brasov, 500152, Romania. Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 9DU, UK. Guy's & Saint Thomas' NHS Foundation Trust, London, UK. Queen's University Belfast, Belfast, BT9 7BL, Ireland. Hematology Division, Washington University, St. Louis, MO 63110, USA. The Alfred Hospital & Monash University, Melbourne 3004, Australia. Leipzig University Hospital, Leipzig, 04103, Germany. Department of Internal Medicine & Center of Integrated Oncology Cologne Bonn, University of Cologne, Köln, 50923, Germany. Center Research & Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Firenze, 50139, Italy. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea. Sierra Oncology, Vancouver, BC, V6C 3E8, Canada. Mays Cancer Center, UT Health San Antonio Cancer Center, San Antonio, TX 78229, USA.

Future oncology (London, England). 2021;(12):1449-1458
Full text from:

Other resources

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Methodological quality

Publication Type : Comparative Study

Metadata

MeSH terms : Primary Myelofibrosis